Changing microbiological picture and sensitivity in otolaryngology in developing world
DOI:
https://doi.org/10.18203/issn.2454-5929.ijohns20210678Keywords:
Microbiology, ENT, Ear discharge, Neck, Abscess, Sensitivity, Antibiotic, PolicyAbstract
Background: Microbiology, culture and sensitivity and antibiotic policy are ever changing in otolaryngology. So, it requires continuous research and modification.
Methods: A retrospective study was conducted at our tertiary care center where microbiology and culture and sensitivity data of patients of chronic otitis media and neck abscess were assessed to form antibiotic policy for the concerned patients. The study comprised of 580 patients of chronic otitis media and 139 patients of neck abscess admitted from October 2018 to December 2019.
Results: Pseudomonas and E. Coli were the most common microbes isolated with most of cases sensitive to Meropenem and Amikacin respectively.
Conclusions: There is a change in microbiological picture and sensitivity to a more resistant type than the previous studies and hence the requirement of modification of antibiotic policy to a more robust one.
References
Pfammatter D, Lüthy R. Modern antibiotic therapy in acute ORL infections. Results of a survey, bacteriological viewpoints and suggestions for antibiotic therapy. Schweiz Med Wochenschr. 1982;112(36):1230-38.
Zelenitsky S, Ariano R, Harding G, Forrest A. Evaluating Ciprofloxacin Dosing for Pseudomonas aeruginosa Infection by Using Clinical Outcome-Based Monte Carlo Simulations, Antimicrob Agents Chemother. 2005;49(10):4009-14.
Ohata Y, Tomita Y, Nakayama M, Kozuki T, Sunakawa K, Tanigawara Y. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/ pharmacodynamic considerations. Drug Metab Pharmacokinet. 2011;26(5):523-31.
Jenkins A, Thomson AH, Brown NM. Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. J Antimicrob Chemother. 2016;71(10):2754-59.
Lamb HM, Ormrod D, Scott LJ, Figgitt DP. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs. 2002;62(7):1041-089.
Mungul S, Maharaj S. Microbiology of paediatric deep neck space infection. Int J Pediatr Otorhinolaryngol. 2019;123:116-22.
George Z, Andrew S, Lavern V, Lionell M. Imipenem and Meropenem: Comparison of In Vitro Activity, Pharmacokinetics, Clinical Trials and Adverse Effects. The Canadian journal of infectious diseases. 1998;9;215-28.
Thabit AK, Grupper M, Nicolau DP, Kuti JL. Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function. J Pharm Pract. 2017;30(6):593-9.
Patel N, Scheetz M G, Drusano G, Lodise T. Identification of Optimal Renal Dosage Adjustments for Traditional and Extended-Infusion Piperacillin-Tazobactam Dosing Regimens in Hospitalized Patients. Antimicrobial Agents and Chemotherapy. 2009;54(1):460-5.
Tulkens PM. Aminoglycoside nephrotoxicity: recent insights and perspectives. Contrib Nephrol. 1984;42:168-81.
Sweileh WM. A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function. Fundam Clin Pharmacol. 2009;23(4):515-20.
Yousif T, Pooyeh S, Hannemann J, Baumann J, Tauber R, Baumann K. Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes. Int J Clin Pharmacol Ther. 1999;37(10):475-86.
Cojocel C, Göttsche U, Tölle KL, Baumann K. Nephrotoxic potential of first-, second-, and third-generation cephalosporins. Arch Toxicol. 1988;62(6):458-64.
Jones RN, Barry AL. Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics. Rev Infect Dis. 1983;5(1):108-26.
